Frontline Axi-Cel Elicits Durable Responses in High-Risk LBCL

Supplements And Featured Publications2021 ASH Annual Meeting: CAR T-Cell Therapy
Volume 1
Issue 1

Frontline treatment with axicabtagene ciloleucel demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma.

Sattva Neelapu, MD

Sattva Neelapu, MD

Frontline treatment with axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated rapid and durable responses in patients with high-risk large B-cell lymphoma (LBCL), according to findings from the phase 2 ZUMA-12 trial (NCT03761056) that were presented during the 2021 American Society of Hematology Annual Meeting & Exposition.1

In the primary analysis, efficacy-evaluable patients, meaning patients with centrally confirmed disease, experienced a high objective response rate (ORR) of 89% and a complete response (CR) rate of 78%, reported lead study author Sattva S. Neelapu, MD, professor in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, during a presentation of the data.1 After a median follow-up of 15.9 months, 73% of patients continued to have a response at data cutoff.

With a median follow-up of 17.4 months (range, 6.0-26.7), investigators found the ORR to be 90% (95% CI, 76%-97%) and the CR rate to be 80% (95% CI, 64%-91%) among all treated patients (n = 40). Among efficacy-evaluable patients (n = 37) at a median follow-up of 15.9 months (range, 6.0-26.7), ORR was 89% (95% CI, 75%-97%) and the CR rate was 78% (95% CI, 62%-90%). Among all-treated patients, the duration of response (DOR), progression-free survival (PFS), and event-free survival (EFS) were not reached. Median overall survival (OS) was 24.5 months.

Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for adults with relapsed or refractory (R/R) LBCL and adults with R/R follicular lymphoma after at least 2 lines of systemic therapy.

Patients were enrolled and given the option to receive nonchemotherapy bridging therapy. Patients were then given conditioning chemotherapy plus axi-cel. The conditioning therapy consisted of 30 mg/m2 of fludarabine intravenously (IV) and 500 mg/m2 of cyclophosphamide IV on days –5, –4, and –3. Patients were then given a single IV of 2 × 106 of axi-cel CAR T cells/kg on day 0. To be considered eligible for ZUMA-12, patients had an IPI score of at least 3 any time before enrollment and a dynamic risk assessment, which included a positive interim PET, with a Deauville score (DS) of 4 or 5, after 2 cycles of an anti-CD20 monoclonal antibody-positive anthracycline-containing regimen. Patients must have had an ECOG score from 0 or 1.

The trial’s primary end point was CR by an investigator-assessed Lugano 2014 classification,2 and its secondary end points were ORR, DOR, EFS, PFS, OS, safety, number of CAR T cells in the blood, and cytokine levels in serum.

The median age of patients was 61 years (range, 23-86) with 38% of patients aged more than 65 years. Of all patients, 68% were male, most (95%) had stage III or IV disease, and 48% had a DS of 4.

Axi-cel’s safety profile was manageable. All patients experienced any-grade adverse events (AEs) with pyrexia (100%), headache (70%), decreased neutrophil count (55%), and nausea (53%) being the most common. Grade 3 or higher AEs occurred in 85% of patients with decreased neutrophil count (53%), decreased white blood cell count (43%), decreased white blood cell count (43%) and anemia (30%) being the most common. One patient contracted COVID-19, labeled as a grade a 5 AE, but was determined to be unrelated to treatment.

Cytokine release syndrome (CRS) was reported in all patients; 8% of cases were grade 3. The most common CRS symptoms were pyrexia (100%), hypotension (30%), and chills (25%). No patients experienced grade 4 or 5 CRS events.

Neurologic events (NEs) occurred in 29 (73%) patients. The most common any-grade symptoms of NEs were confused state (28%), encephalopathy (25%), and tremor (25%). Grade 2 or higher NEs were seen in 38% of patients, grade 3 or higher NEs were seen in 23% of patients, 2 patients experienced a grade 4 NE, and no patients experienced a grade 5 NE.

The median number of CAR T cells infused was 165 (range, 95-200) × 106, and the median number of CCR7+CD45RA+ T cells infused was 105 (range, 33-254) × 106. Investigators found an association with levels of CCR7+CD45RA+ T cells in preinfusion with a favorable pharmacokinetic profile.3

Investigators concluded that axi-cel may benefit patients with high-risk LBCL who were exposed to fewer prior therapies. These results warrant further trials of axi-cel in the first-line setting.


  1. Neelapu S, Dickinson M, Munoz J, et al. Primary analysis of zuma-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as first-line therapy in patients with high-risk large b-cell lymphoma (LBCL). Presented at: 2021 ASH Annual Meeting and Exposition; December 11-14, 2021; Atlanta, GA. Abstract 739
  2. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119-3128. doi:10.1200/JCO.19.02104
  3. Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898-4911. doi:10.1182/bloodadvances.2020002394 Abstract 739
Related Videos
Peter Schmid, MD, PhD
Seema A. Khan, MD
Stephanie L. Graff, MD
Senthil Damodaran, MD, PhD
Jason Jincong Freeman, PhD
Heather A. Parsons, MD, MPH
Nicole Lamanna, MD, a hematologist-oncologist
Joseph P. McGuirk, DO, an expert on lymphoma